Pluristem is one of the companies focusing on the commercial development of stem cells. There are two or three names which have been regularly sending out press releases concerning their research and development (besides ACT, of course).
In this case, it’s a company that’s marketing selected umbilical cord blood cells or placental cells. If the product turns out to be what they say it is – a population of adult or fetal cells that can be harvested from the placenta after a child is safely born, isolated by the company’s secret method, and transplanted to replace or supplement diseased bone marrow – then the complication of rejection may soon be a thing of the past:
Pluristem Announces Evidence That PLX-I Cells Are Immune Privileged
NEW YORK–(BUSINESS WIRE)–Jan 29, 2007 – Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced evidence that its PLX-I cells have proven to be immune privileged. PLX-I cells are Pluristem’s first potential product dedicated to resolving the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood. PLX-I cells are mesenchymal stems cells obtained from the placenta and expanded by using Pluristem’s proprietary 3D PluriX(TM) technology.
“Immune privileged” is defined as the absence or diminution of rejection when implanted into unmatched recipients. Being immune privileged, the PLX-1 cells carry significant positive implications in the development of Company products for a variety of degenerative, malignant and immune diseases. Additionally, this immune modulating property could prove important in treating or preventing immune reactions associated with transplantation.
Ora Burger PhD. V.P. of R&D at Pluristem states: “Our PLX-I cells possess immune privileged characteristics that can be used in the future for other applications involving transplantations. PLX-I cells posses[s] these immune privileged characteristics without carrying the associated social stigmata of embryonic stem cells because PLX-I cells come from the placenta.”
William R. Prather RPh, MD, Sr. V.P. Corporate Development notes: “Mesenchymal stem cells can differentiate into a range of different tissues types associated with the musculoskeletal system such as bone, cartilage, fat, muscle, tendon and ligament. Consequently, mesenchymal stem cells are considered to be multipotent. Additionally, some reports provide evidence of these cells plasticity or the ability of mesenchymal stem cells to traverse tissue boundaries and give rise to cells of a different non-musculoskeletal tissue, such as brain or liver cells. If this is the case, mesenchymal stem cells may be used to help treat a broad range of tissues affected by damage or disease. Allogeneic transplantation of mesenchymal stem cells between different individuals may also be possible as these cells appear to be immune privileged in that they are not necessarily rejected when implanted into unmatched recipients. The characteristic of these cells being immune privileged may enable Pluristem to be involved with new clinical applications with PLX-I.”